Shots:
Hengrui Pharma has entered into a license agreement with Novo for HRS-1596, a P-I-ready GLP-1 receptor & gastric inhibitory polypeptide receptor dual agonist, with potential for QW oral dosing
As per the deal, Novo will obtain exclusive rights to develop, manufacture & commercialize HRS-1596 globally, excl. Mainland China, the Hong Kong SAR, the Macao…
